Jubilant Pharmova LtdNSE: JUBLPHARMA
Open the Jubilant Pharmova Ltd page
Follow Jubilant Pharmova LtdFree account. Get a note when Jubilant Pharmova Ltd files.
Q1 FY27 results analysis · August 10, 2026

Jubilant Pharmova Ltd (JUBLPHARMA) Q1 FY27 Results Analysis: PAT Plunges 45%, Margin Collapses 410 bps

−45.1%PAT year on year, Rs. 56.50 Cr
Cofacto ResearchPublished August 10, 20262 min readNegative read
Quick summary

Jubilant Pharmova Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 2,229.40 Cr (+17.30% YoY) and PAT growth of -45.10% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 10, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 2,229.40 Cr (+17.30% YoY)
PAT (Q1)Rs. 56.50 Cr (-45.10% YoY)
EBITDA margin11.10% (-410 bps YoY)
EPS (Q1)Rs. 3.57 (-45.00% YoY)
Market capRs. 15,339.93 Cr
CMPRs. 962.70

Quarter Snapshot

Revenue grew 17.3% YoY but EBITDA margin collapsed 410 bps to 11.1% and PAT declined 45.1% YoY. Margin pressure from SPECT shortage, Montreal FDA warning letter, and cost inflation overshadowed segment growth. Management's H2 margin recovery guidance faces steep headwinds.

Key Investment Insights

Key Positives

  • Revenue grew 17.3% YoY to Rs.2,229.4 Cr
  • Radiopharma segment revenue grew 17.7% YoY
  • CDMO Sterile Injectables revenue surged 32.4% YoY
  • Allergy Immunotherapy grew 12% YoY, gaining market share
  • CRDMO margin improved from 8.7% to 10.9%

Risk Factors

  • EBITDA margin collapsed 410 bps YoY to 11.1%
  • PAT attributable to owners declined 45.1% YoY
  • CDMO Sterile Injectables EBIT margin collapsed to 1.4% from 11.0% YoY
  • Generics segment swung to EBIT loss of Rs.10.1 Cr
  • Radiopharma EBIT margin fell from 11.4% to 7.6% due to SPECT shortage
  • Employee costs rose 27.5% YoY, outpacing revenue growth

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.